T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

This study tests whether adding either dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs …

This early-phase trial tests whether adding the drug daratumumab after a stem cell transplant is safe for children, teens, and young adults with high-risk T-cell acute lymphoblastic leukemia or lymphoma. Participants first receive high-dose chemotherapy and total body irradiation…

This study tests a drug called daratumumab for people with T-cell acute lymphoblastic leukemia (T-ALL) who still have tiny amounts of cancer left after chemotherapy. The goal is to see if the drug can wipe out these leftover cells and lead to a complete remission. About 20 partic…

This study tests whether combining two drugs, venetoclax and azacitidine, can help people newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). About 28 participants aged 15 and older will receive the treatment to see how many achieve remission. The goal is to control…

This study tests a new treatment using specially engineered immune cells (CD7 CAR T-cells) for people with T-cell cancers that have come back or not responded to standard therapy. The cells are made from the patient's own blood or from a donor. The goal is to see if this treatmen…

This early-phase trial is testing whether a new type of CAR T-cell therapy, made from a patient's own blood cells, is safe for children and adults with T-cell leukemia or lymphoma that has come back or not responded to standard treatments. The therapy targets a protein called CCR…

This early-phase study tests a new treatment for people with T-cell leukemia or lymphoma that has come back. Doctors take a patient's (or their donor's) immune cells, add a special receptor that helps them recognize and attack cancer cells, and give them back. The goal is to see …

This early-stage trial tests a new treatment for people with T-cell leukemia or lymphoma that has come back or not responded to standard therapy. Doctors take a patient's own immune cells (T cells), modify them in the lab to recognize and attack cancer cells carrying the CD7 prot…

This early-phase study tests a new treatment for people with T-cell leukemia or lymphoma that has come back. The treatment uses the patient's own immune cells (T cells) that have been modified in a lab to recognize and attack cancer cells carrying a protein called CD7. The goal i…

This study tests whether a combination of three drugs (calaspargase pegol-mknl, decitabine, and venetoclax) can help control relapsed or treatment-resistant T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children, teens, and young adults up to age 21. Th…

This early study tests a new treatment called OC-1, which uses a patient's own immune cells that have been specially trained to find and attack a protein (CD1a) on cancer cells. The trial aims to see if OC-1 is safe and can help up to 20 children and adults whose T-cell acute lym…

This study tests a treatment called WU-CART-007 for people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or not responded to other treatments. The therapy uses donor immune cells that are modified to find and attack cancer cells. The main g…